Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-848-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$967.58 million
Profitability
Miscellaneous
Employees3,216
Next Earnings Date11/1/2019 (Confirmed)
OptionableOptionable
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics declared that its board has authorized a stock repurchase plan on Tuesday, February 6th 2018, which permits the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics Co. (NYSE:HAE) released its quarterly earnings data on Tuesday, August, 6th. The medical instruments supplier reported $0.81 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.18. The medical instruments supplier had revenue of $238.50 million for the quarter, compared to analyst estimates of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. Haemonetics's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 EPS. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
How can I listen to Haemonetics' earnings call?
Haemonetics will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics issued an update on its FY20 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $2.95-3.15 for the period, compared to the Thomson Reuters consensus estimate of $2.94. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.00 billion.
What price target have analysts set for HAE?
5 Wall Street analysts have issued 12 month target prices for Haemonetics' stock. Their forecasts range from $139.00 to $150.00. On average, they anticipate Haemonetics' stock price to reach $144.40 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Haemonetics.
What is the consensus analysts' recommendation for Haemonetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.
What are Wall Street analysts saying about Haemonetics stock?
Here are some recent quotes from research analysts about Haemonetics stock:
- 1. According to Zacks Investment Research, "Haemonetics registered encouraging growth at the Plasma and Hospitals segments in its third-quarter, fiscal 2019, However, sluggish Blood Center business moderated overall growth in the reporting cycle. Moreover, tough competitive environment also weighed on the stock. On a positive note, Haemonetics promising third-quarter fiscal 2019 result benefitted from complexity reduction and investments, along with strength in market demand and success from early launches, helped the company put up an impressive performance. Continued momentum in business generation and geographical expansion contributed to results. We are upbeat about the company’s steady progress, with the launch of NexSys PCS devices and NexLynk DMS donor management software. Over the past year, Haemonetics has been outperforming its industry." (4/9/2019)
- 2. Barrington Research analysts commented, "We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus)." (10/5/2018)
Has Haemonetics been receiving favorable news coverage?
News coverage about HAE stock has been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Haemonetics earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Haemonetics.
Are investors shorting Haemonetics?
Haemonetics saw a drop in short interest in August. As of August 15th, there was short interest totalling 798,900 shares, a drop of 29.8% from the July 15th total of 1,138,500 shares. Based on an average daily volume of 466,000 shares, the short-interest ratio is presently 1.7 days. Approximately 1.6% of the shares of the stock are sold short. View Haemonetics' Current Options Chain.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Nevro (NVRO).
What other stocks do shareholders of Haemonetics own?
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, CEO, Pres & Director (Age 55)
- Mr. William P. Burke, CFO & Exec. VP
- Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
- Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)
Who are Haemonetics' major shareholders?
Haemonetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.82%), BlackRock Inc. (11.82%), Vanguard Group Inc. (11.02%), Renaissance Technologies LLC (4.89%), Wells Fargo & Company MN (2.20%) and Eminence Capital LP (1.73%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.
Which major investors are selling Haemonetics stock?
HAE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., AQR Capital Management LLC, BlackRock Inc., BlackRock Inc., Panagora Asset Management Inc., Prudential Financial Inc., Morgan Stanley and Westfield Capital Management Co. LP. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.
Which major investors are buying Haemonetics stock?
HAE stock was acquired by a variety of institutional investors in the last quarter, including Eminence Capital LP, Nuveen Asset Management LLC, Invesco Ltd., Wells Fargo & Company MN, Castleark Management LLC, Renaissance Technologies LLC, Marshall Wace LLP and Tamarack Advisers LP. View Insider Buying and Selling for Haemonetics.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $129.44.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $6.57 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.
What is Haemonetics' official website?
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (NYSE HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
